Kumar Balasubramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kumar Balasubramanian has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Philip James Devereaux
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
3 shared publications - Alben Sigamani
Carmel Research Consultancy Pvt Ltd, Bengaluru, India
2 shared publications - Ameen Patel
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
2 shared publications - Ernesto Guerra-Farfán
Department of Orthopaedic Surgery and Traumatology, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
2 shared publications - Flavia Kessler Borges
Department of Medicine, McMaster University, Hamilton, ON, Canada
2 shared publications - Gerard P. Slobogean
Department of Orthopaedic Surgery, University of California, Irvine, Irvine, CA
2 shared publications
Latest Publications
- 27 October 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (2) , 289-300
Pain as a Driver of Myocardial Injury in Hip Fracture Patients: A Hip Fracture Accelerated Surgical Treatment and Care Track (HIP ATTACK) Trial Secondary Analysis
Background: Pain is a common yet underaddressed issue in surgical inpatients. Inadequate pain control in patients with hip fractures can lead to adverse hemodynamic changes, potentially increasing the risk of myocardial ischemia. The authors aim to investigate whether perioperative pain is associated with the development of myocardial ischemic events in patients undergoing hip fracture surgery. Methods: HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) was a multicenter international randomized controlled trial comparing the effects of accelerated surgical repair of hip fracture versus standard of care. The authors included patients enrolled in the HIP ATTACK trial who had at least one troponin measurement and a pain score measurement. Pain was assessed daily on hospital admission using the 0 to 10 numeric rating scale. The primary analysis included all available pain scores averaged (then categorized as mild [numeric rating scale 0 to 3], moderate [4 to 7], and severe [8 to 10] pain) before and on the day of the first troponin elevation. The primary outcome was troponin elevation from any cause, with secondary outcomes of myocardial injury (due to an ischemic etiology), myocardial infarction, and then a composite of myocardial injury and myocardial infarction. Multivariable regression models adjusting for potential confounders were used to identify an association between pain categories and outcomes. Results: The authors included 2,430 (82%) from the initial HIP ATTACK cohort (n = 2,970). Forty-five percent of patients (1,098) suffered a troponin elevation from any cause. In the adjusted models, moderate (odds ratio, 3.90; 95% CI, 3.02 to 5.05) and severe pain (odds ratio, 29.24; 95% CI, 17.7 to 48.29) were associated with a troponin elevation of any cause. Similarly, moderate (odds ratio, 2.09; 95% CI, 1.71 to 2.57) and severe pain (odds ratio, 6.04, 95% CI, 4.49 to 8.12) were associated with myocardial injury, whereas only severe pain was associated with myocardial infarction (odds ratio, 2.33; 95% CI, 1.35 to 3.99). Both moderate and severe pain were associated with the composite outcome. Conclusions: Increased pain may be associated with myocardial ischemic events in the perioperative period in hip fracture patients. Future research is needed to confirm and further clarify this relationship and to determine whether analgesic interventions can reduce the risk of perioperative myocardial ischemia.
- 27 October 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 144 (2) , 289-300
Pain as a Driver of Myocardial Injury in Hip Fracture Patients: A Hip Fracture Accelerated Surgical Treatment and Care Track (HIP ATTACK) Trial Secondary Analysis
Background: Pain is a common yet underaddressed issue in surgical inpatients. Inadequate pain control in patients with hip fractures can lead to adverse hemodynamic changes, potentially increasing the risk of myocardial ischemia. The authors aim to investigate whether perioperative pain is associated with the development of myocardial ischemic events in patients undergoing hip fracture surgery. Methods: HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) was a multicenter international randomized controlled trial comparing the effects of accelerated surgical repair of hip fracture versus standard of care. The authors included patients enrolled in the HIP ATTACK trial who had at least one troponin measurement and a pain score measurement. Pain was assessed daily on hospital admission using the 0 to 10 numeric rating scale. The primary analysis included all available pain scores averaged (then categorized as mild [numeric rating scale 0 to 3], moderate [4 to 7], and severe [8 to 10] pain) before and on the day of the first troponin elevation. The primary outcome was troponin elevation from any cause, with secondary outcomes of myocardial injury (due to an ischemic etiology), myocardial infarction, and then a composite of myocardial injury and myocardial infarction. Multivariable regression models adjusting for potential confounders were used to identify an association between pain categories and outcomes. Results: The authors included 2,430 (82%) from the initial HIP ATTACK cohort (n = 2,970). Forty-five percent of patients (1,098) suffered a troponin elevation from any cause. In the adjusted models, moderate (odds ratio, 3.90; 95% CI, 3.02 to 5.05) and severe pain (odds ratio, 29.24; 95% CI, 17.7 to 48.29) were associated with a troponin elevation of any cause. Similarly, moderate (odds ratio, 2.09; 95% CI, 1.71 to 2.57) and severe pain (odds ratio, 6.04, 95% CI, 4.49 to 8.12) were associated with myocardial injury, whereas only severe pain was associated with myocardial infarction (odds ratio, 2.33; 95% CI, 1.35 to 3.99). Both moderate and severe pain were associated with the composite outcome. Conclusions: Increased pain may be associated with myocardial ischemic events in the perioperative period in hip fracture patients. Future research is needed to confirm and further clarify this relationship and to determine whether analgesic interventions can reduce the risk of perioperative myocardial ischemia.
- 25 July 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (24) , 2303-2312
Myocardial Injury in Patients with Hip Fracture
Background: Myocardial injury after a hip fracture is common and has a poor prognosis. Patients with a hip fracture and myocardial injury may benefit from accelerated surgery to remove the physiological stress associated with the hip fracture. This study aimed to determine if accelerated surgery is superior to standard care in terms of the 90-day risk of death in patients with a hip fracture who presented with an elevated cardiac biomarker/enzyme measurement at hospital arrival. Methods: The HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) trial was a randomized controlled trial designed to determine whether accelerated surgery for hip fracture was superior to standard care in reducing death or major complications. This substudy is a post-hoc analysis of 1392 patients (from the original study of 2970 patients) who had a cardiac biomarker/enzyme measurement (>99.9% had a troponin measurement and thus “troponin” is the term used throughout the paper) at hospital arrival. The primary outcome was all-cause mortality. The secondary composite outcome included all-cause mortality and non-fatal myocardial infarction, stroke, and congestive heart failure 90 days after randomization. Results: Three hundred and twenty-two (23%) of the 1392 patients had troponin elevation at hospital arrival. Among the patients with troponin elevation, the median time from hip fracture diagnosis to surgery was 6 hours (interquartile range [IQR] = 5 to 13) in the accelerated surgery group and 29 hours (IQR = 19 to 52) in the standard care group. Patients with troponin elevation had a lower risk of mortality with accelerated surgery compared with standard care (17 [10%] of 163 versus 36 [23%] of 159; hazard ratio [HR] = 0.43 [95% confidence interval (CI) = 0.24 to 0.77]) and a lower risk of the secondary composite outcome (23 [14%] of 163 versus 47 [30%] of 159; HR = 0.43 [95% CI = 0.26 to 0.72]). Conclusions: One in 5 patients with a hip fracture presented with myocardial injury. Accelerated surgery resulted in a lower mortality risk than standard care for these patients; however, these findings need to be confirmed. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- 25 July 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 106 (24) , 2303-2312
Myocardial Injury in Patients with Hip Fracture
Background: Myocardial injury after a hip fracture is common and has a poor prognosis. Patients with a hip fracture and myocardial injury may benefit from accelerated surgery to remove the physiological stress associated with the hip fracture. This study aimed to determine if accelerated surgery is superior to standard care in terms of the 90-day risk of death in patients with a hip fracture who presented with an elevated cardiac biomarker/enzyme measurement at hospital arrival. Methods: The HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) trial was a randomized controlled trial designed to determine whether accelerated surgery for hip fracture was superior to standard care in reducing death or major complications. This substudy is a post-hoc analysis of 1392 patients (from the original study of 2970 patients) who had a cardiac biomarker/enzyme measurement (>99.9% had a troponin measurement and thus “troponin” is the term used throughout the paper) at hospital arrival. The primary outcome was all-cause mortality. The secondary composite outcome included all-cause mortality and non-fatal myocardial infarction, stroke, and congestive heart failure 90 days after randomization. Results: Three hundred and twenty-two (23%) of the 1392 patients had troponin elevation at hospital arrival. Among the patients with troponin elevation, the median time from hip fracture diagnosis to surgery was 6 hours (interquartile range [IQR] = 5 to 13) in the accelerated surgery group and 29 hours (IQR = 19 to 52) in the standard care group. Patients with troponin elevation had a lower risk of mortality with accelerated surgery compared with standard care (17 [10%] of 163 versus 36 [23%] of 159; hazard ratio [HR] = 0.43 [95% confidence interval (CI) = 0.24 to 0.77]) and a lower risk of the secondary composite outcome (23 [14%] of 163 versus 47 [30%] of 159; HR = 0.43 [95% CI = 0.26 to 0.72]). Conclusions: One in 5 patients with a hip fracture presented with myocardial injury. Accelerated surgery resulted in a lower mortality risk than standard care for these patients; however, these findings need to be confirmed. Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 24 October 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (17) , 1298-1304
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
BACKGROUND: LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation undergoing cardiac surgery. This article examines the effect of LAA occlusion on stroke reduction according to variation in the use of oral anticoagulant (OAC) therapy. METHODS: Information regarding OAC use was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks of hospital discharge, 1 and 2 years after randomization, evaluated the effect of LAA occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use. Adjusted proportional hazard modeling, with OAC use as a time-dependent covariate, was also performed to assess the effect of LAA occlusion, according to OAC use throughout the study. RESULTS: At hospital discharge, 3027 patients (63.5%) were receiving a vitamin K antagonist, and 879 (18.5%) were receiving a non–vitamin K antagonist oral anticoagulant (direct OAC), with no difference in OAC use between treatment arms. There were 2887 (60.5%) patients who received OACs at all follow-up visits, 1401 (29.4%) who received OAC at some visits, and 472 (9.9%) who never received OACs. The effect of LAA occlusion on the risk of ischemic stroke or systemic embolism was consistent after discharge across all 3 groups: hazard ratios of 0.70 (95% CI, 0.51–0.96), 0.63 (95% CI, 0.43–0.94), and 0.76 (95% CI, 0.32–1.79), respectively. An adjusted proportional hazards model with OAC use as a time-dependent covariate showed that the reduction in stroke or systemic embolism with LAA occlusion was similar whether patients were receiving OACs or not. CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.
- 24 October 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (17) , 1298-1304
Open AccessOral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
BACKGROUND: LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with atrial fibrillation undergoing cardiac surgery. This article examines the effect of LAA occlusion on stroke reduction according to variation in the use of oral anticoagulant (OAC) therapy. METHODS: Information regarding OAC use was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks of hospital discharge, 1 and 2 years after randomization, evaluated the effect of LAA occlusion on the risk of ischemic stroke or systemic embolism, according to OAC use. Adjusted proportional hazard modeling, with OAC use as a time-dependent covariate, was also performed to assess the effect of LAA occlusion, according to OAC use throughout the study. RESULTS: At hospital discharge, 3027 patients (63.5%) were receiving a vitamin K antagonist, and 879 (18.5%) were receiving a non–vitamin K antagonist oral anticoagulant (direct OAC), with no difference in OAC use between treatment arms. There were 2887 (60.5%) patients who received OACs at all follow-up visits, 1401 (29.4%) who received OAC at some visits, and 472 (9.9%) who never received OACs. The effect of LAA occlusion on the risk of ischemic stroke or systemic embolism was consistent after discharge across all 3 groups: hazard ratios of 0.70 (95% CI, 0.51–0.96), 0.63 (95% CI, 0.43–0.94), and 0.76 (95% CI, 0.32–1.79), respectively. An adjusted proportional hazards model with OAC use as a time-dependent covariate showed that the reduction in stroke or systemic embolism with LAA occlusion was similar whether patients were receiving OACs or not. CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.
- Open Access
- 4 January 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1)
Clinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study
A wide knowledge gap exists on the clinical profiles and outcomes of heart failure (HF) in sub-Saharan Africa. To determine the clinical profiles and outcomes of HF patients from five African countries. The INTERnational Congestive Heart Failure Study (INTER-CHF) is a prospective, multicenter cohort study. A total of 1,294 HF patients were consecutively recruited from Nigeria (383 patients), South Africa (169 patients), Sudan (501 patients), Uganda (151patients), and Mozambique (90 patients). HF was defined according to the Boston criteria for diagnosis. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) score. Of the 1294 patients, 51.4% were recruited as out-patients, 53.7% had HF with reduced ejection fraction (EF), 30.1% had HF with mid-range EF and 16.2% had HF with preserved EF (16.2%). The commonest etiologies of HF were hypertensive heart disease (35%) and ischemic heart disease (20%). The mean MoCA score was highest in Uganda (24.3 ± 1.1) and lowest in Sudan (13.6 ± 0.3). Prescriptions for guideline-recommended HF therapies were poor; only 1.2% of South African patients received an Implantable Cardioverter Defibrillator, and none of the patients received Cardiac Resynchronised Therapy. The composite outcome of death or HF hospitalization at one year among the patients was highest in Sudan (59.7%) and lowest in Mozambique (21.1%). Six variables were associated with higher mortality risk, while digoxin use (adjusted hazard ratio [aHR]: 0.69; 95% confidence interval [CI]: 0.49–0.97; p = 0.034) and 10mmHg unit increase in systolic blood pressure (aHR 0.86; 95%CI 0.81–0.93; p < 0.001) were associated with lower risk for mortality. This is the largest HF study in Africa that included in- and out-patients from the West, East, North, Central and South African sub-regions. Clinically relevant differences, including cognitive functional impairment, were found between the involved countries.
- 4 January 2021
- Published by Ubiquity Press, Ltd. in Global Heart
- Vol. 16 (1)
Open AccessClinical Profiles and Outcomes of Heart Failure in Five African Countries: Results from INTER-CHF Study
A wide knowledge gap exists on the clinical profiles and outcomes of heart failure (HF) in sub-Saharan Africa. To determine the clinical profiles and outcomes of HF patients from five African countries. The INTERnational Congestive Heart Failure Study (INTER-CHF) is a prospective, multicenter cohort study. A total of 1,294 HF patients were consecutively recruited from Nigeria (383 patients), South Africa (169 patients), Sudan (501 patients), Uganda (151patients), and Mozambique (90 patients). HF was defined according to the Boston criteria for diagnosis. Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) score. Of the 1294 patients, 51.4% were recruited as out-patients, 53.7% had HF with reduced ejection fraction (EF), 30.1% had HF with mid-range EF and 16.2% had HF with preserved EF (16.2%). The commonest etiologies of HF were hypertensive heart disease (35%) and ischemic heart disease (20%). The mean MoCA score was highest in Uganda (24.3 ± 1.1) and lowest in Sudan (13.6 ± 0.3). Prescriptions for guideline-recommended HF therapies were poor; only 1.2% of South African patients received an Implantable Cardioverter Defibrillator, and none of the patients received Cardiac Resynchronised Therapy. The composite outcome of death or HF hospitalization at one year among the patients was highest in Sudan (59.7%) and lowest in Mozambique (21.1%). Six variables were associated with higher mortality risk, while digoxin use (adjusted hazard ratio [aHR]: 0.69; 95% confidence interval [CI]: 0.49–0.97; p = 0.034) and 10mmHg unit increase in systolic blood pressure (aHR 0.86; 95%CI 0.81–0.93; p < 0.001) were associated with lower risk for mortality. This is the largest HF study in Africa that included in- and out-patients from the West, East, North, Central and South African sub-regions. Clinically relevant differences, including cognitive functional impairment, were found between the involved countries.
- 15 November 2011
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 31 (8) , 769-770
Giant lingual granuloma gravidarum
(2011). Giant lingual granuloma gravidarum. Journal of Obstetrics and Gynaecology: Vol. 31, No. 8, pp. 769-770. doi: 10.3109/01443615.2011.615419
- 15 November 2011
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 31 (8) , 769-770
Giant lingual granuloma gravidarum
(2011). Giant lingual granuloma gravidarum. Journal of Obstetrics and Gynaecology: Vol. 31, No. 8, pp. 769-770. doi: 10.3109/01443615.2011.615419